Deep Dive: Deep Dive Into Pegcetacoplan

Twenty-four month data from the DERBY and OAKS studies better indicate the overall safety of pegcetacoplan for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Pegcetacoplan is an investigational, targeted C3 therapy, studied in over 1200 patients between the two phase 3 studies. The safety data were presented at the 2022 American Academy of Ophthalmology Meeting in Chicago. In an interview with HCPLive, presenting author David Boyer, MD, Senior Partner, Retina-Vitreous Associates Medical Group, discussed the observed safety signals and their connection to the greater benefit of the drug.